Breast Cancer
Randomized Phase II Trial of Letrozole with or without Dasatinib as First and Second-Line Treatment for Hormone Receptor-Positive, HER2-Negative Post-Menopausal Breast Cancer that is Unresectable, Locally Recurrent or Metastatic
Trial ID: 06185
Contact: Carolyn Cox
Phone: (281)863-6641
Learn More about this trial.
go back | new search